Aligos Therapeutics wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col FAASLD, who served as a trusted advisor and the Principal Investigator for the Company’s ongoing Phase 2a HERALD study in metabolic dysfunction-associated steatohepatitis subjects. Thanks to Dr. Harrison’s expertise in designing and implementing HERALD, the study is continuing to enroll, dose subjects, and remains on track for the anticipated topline data readout in Q4 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos dosing initiated in Phase 2a HERALD study of ALG-055009, data due in Q4
- Aligos presents data at APASL 2024 from ALG-055009, ALG-000184 studies
- Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Aligos Therapeutics initiates Phase 2a HERALD study of ALG-055009
- Aligos Therapeutics on the Brink: The Urgent Race to Maintain Nasdaq Listing and Avoid Delisting Consequences